The biotech is now banking on secondary data signals as it progresses ignaseclant to late-stage trials in Charcot-Marie-Tooth ...

NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...

The DGIST Center for Synapse Diversity and Specificity has identified MDGA2 as a novel causative gene for developmental and epileptic encephalopathy (DEE), a rare and intractable neurological disorder ...

Professor Jaewon Ko’s research team at DGIST, in collaboration with international researchers, identified that the loss of function of the MDGA2 gene induces severe developmental and epileptic encepha ...

Traumatic spinal cord injury (SCI) is a serious neurologic disorder that can result in long-term motor and sensory ...